87 results about "Anxiety depression" patented technology

The present invention is a method for the treatment of eating disorders by nerve tissue stimulation and infusion techniques to one or more areas of the brain affecting hunger and satiety; palatability and aversion; hedonism; reward / addiction behavior; mood; anxiety; depression, taste and smell. The invention also comprises methods for the treatment of disorders of these individual behaviors and in particular, disorders of taste and / or smell.

The present invention relates to methods and compositions for reducing Distress Dysfunction by restoring and maintaining homeostatic balance in the neurotransmitter systems underlying the Stress Response and the experience of distress and hedonic tone. Distress Dysfunction refers to the experience of dysfunctional emotional and physical distress that interferes with the individual's quality of life and functioning. A novel understanding of the bimodal opioid modulation of pain, and its impact, through serotonergic, dopaminergic, epinephrinergic, and norepinephrinergic processes, on hedonic tone, leads directly to new generation pharmaceutical formulations that are remarkably safe and effective for the treatment of a wide variety of Distress Dysfunctions, including anxiety, depression, anger, insomnia, mood disorders, eating disorders, sexual problems, pain, substance and behavioral addictions, gastrointestinal disorders, autistic spectrum disorders, attention-deficit and hyperactivity disorders, and other emotional and physical distress disorders. The foundation of this discovery is the power of Receptor Switchers, such as ultra-low-dose and very-low-dose opioid antagonists and GM1 ganglioside attenuators, in blocking acute and protracted excitatory opioid receptor signaling. Co-administration of Receptor Switchers with Endorphin Enhancers, such as specific cAMP PDE inhibitors and excitatory amino acids, is an excellent formulation for restoring healthy homeostatic balance to the endogenous opioid system, using the body's endorphins to reduce emotional and physical distress, and through synergistic and homeostatic processes, restoring positive hedonic tone. The addition of Synergistic Enhancers, such as amino acids, SSRI and SNRI agents, and non-opioid analgesics, as well as Exogenous Opioids, enhances and prolongs these therapeutic benefits. The novel principles discovered by this invention also teach a new generation of safe and effective formulations for the treatment of respiratory conditions, neuropathy, and nociceptive pain.

Provided is a strain CCFM8630 of Bifidobacterium adolescentis and use thereof. The strain CCFM8630 of Bifidobacterium adolescentis can significantly increase neurotransmitter 5-hydroxytryptamine level in peripheral blood of rat, recover the hormone levels, for example testosterone and so on in peripheral blood of rat, normalize abnormal abundances of Bifidobacterium genus, Blautia genus and Turicibacter genus in intestinal flora of rat affected by high-fat high-starch diet, show pretty good tolerance to simulated gastrointestinal fluid and quickly colonize in intestinal, significantly improve pathological damages of tissues such as liver, duodenum and so on, and increase triglyceride and total cholesterol levels in serum and oral glucose tolerance of rat with metabolic syndrome caused by high-fat high-starch diet. The strain CCFM8630 of Bifidobacterium adolescentis can be used for preventing, relieving or treating metabolic disorder, such as metabolic syndrome, irritable bowel syndrome and mental diseases related to metabolic syndrome such as anxiety, depression and so on.

The present invention discloses the identification of a human autism susceptibility gene, which can be used for the diagnosis, prevention and treatment of autism and related disorders, as well as for the screening of therapeutically active drugs. The invention more specifically discloses that the PITX1 gene on chromosome 5 and certain alleles thereof are related to susceptibility to autism and represent novel targets for therapeutic intervention. The present invention relates to particular mutations in the PITX1 gene and expression products, as well as to diagnostic tools and kits based on these mutations. The invention can be used in the diagnosis of pervasive developmental disorder, mental retardation, anxiety, depression, attention deficit hyperactivity disorders, speech delay, epilepsy, metabolic disorder, immune disorder, bipolar disease and other psychiatric and neurological diseases.

The present invention relates to 2-Aminoquinoline derivatives of general formula Iand pharmaceutically-acceptable acid-addition salts thereof, wherein R1, R2 and X are as defined in the specification. The compounds may be used as 5-HT5A receptor antagonists. The present invention relates also to processes for making such a compound and a pharmaceutical composition comprising such a compound. Compounds of the present invention are useful in the prevention and / or treatment of anxiety depression, anxiety disorders, schizophrenia, panic disorders, agoraphobia, social phobia, obsessive compulsive disorders, post-traumatic stress disorders, pain, memory disorders, dementia, disorders of eating behaviors, sexual dysfunction, sleep disorders, withdrawal from abuse of drugs, motor disorders such as Parkinson's disease, psychiatric disorders and gastrointestinal disorders.

The invention relates to a new curative application of a traditional Chinese medicine, in particular to the dual-cordis effect treatment of Xin Keshu as a traditional Chinese medicine. The traditional Chinese medicine has new curative application to patients accompanied with adverse moods, such as worry, depression, and the like.

The invention relates to a medicine for treating anxiety and depressive disorder, which is prepared by the following crude medicines according to parts by weight: 6-20 parts of radix bupleuri, 6-20 parts of radix paeoniae alba and 6-15 parts of white atractylodes rhizome; and the medicine further comprises 6-15 parts of selfheal, 3-6 parts of coptis chinensis and 3-6 parts of cinnamon. The invention further provides an application of the medicine in preparing medicine for treating anxiety and depressive disorder. The medicine is prepared by pure traditional Chinese medicine and based on enough traditional Chinese medicine and western medicine theories; the anxiety and depressive disorder is treated by concerning the morbidity background of the whole disease and the causa morbi and mechanism instead of being treated by the description of the disease; the curative effect is obvious by going deep into the base; the medicine has the same medicine strength as western medicine, so the medicine has no toxic or side effects; the medicine is easily accepted by sufferers; and with the advantages of less crude medicine components, easiness in obtaining, low cost and simple preparation process, the medicine can be popularized and used.

The invention discloses a method for analyzing emotion anxiety, depression and tension based on AR artificial intelligence, and the method comprises the following steps: temporary data collection, sleep data collection, sound emotion collection, sound data processing, resting test collection, deep breath data collection, motion test, and data import processing. Wherein the temporary data acquisition comprises the following steps: firstly, carrying out a five-minute resting test, recording electrocardiogram pulse wave data of a testee in a resting state by a data acquisition platform, normally breathing for 30 seconds, and then carrying out a one-minute deep breathing test. According to the method for analyzing emotion anxiety, depression and tension based on AR artificial intelligence, switching collection can be accurately conducted on static and moving physiological data, the collection accuracy is improved, emotion anxiety, depression and tension analysis is more accurately conducted, sleep data and sound emotion data of a patient can be collected, the types of analysis are increased, and the analysis of emotion anxiety, depression and tension can be more reliably carried out.

The present invention discloses the identification of a human autism susceptibility gene, which can be used for the diagnosis, prevention and treatment of autism and related disorders, as well as for the screening of therapeutically active drugs. The invention more specifically discloses that the PRKCB1 gene of chromosome 16 and certain alleles thereof are related to susceptibility to autism and represent novel targets for therapeutic intervention. The present invention relates to particular mutations in the PRKCB1 gene and expression products, as well as to diagnostic tools and kits based on these mutations. The invention can be used in the diagnosis of predisposition to, detection, prevention and / or treatment of Asperse syndrome, pervasive developmental disorder, childhood disintegrate disorder, mental retardation, anxiety, depression, attention deficit hyperactive disorders, speech delay or language impairment, epilepsy, metabolic disorder, immune disorder, bipolar disease and other psychiatric and neurological disease.

The invention discloses a preparation process of organic acid lithium-L-proline salt, and relates to the field of synthesis and preparation of organic lithium salt micromolecular medicines. The lithium isobutyrate-L-proline salt is prepared by adopting a single solvent method and a mixed solvent method so as to achieve the purposes of development and clinical application of new organic lithium salt. The organic acid lithium-L-proline salt has positive curative effects and prevention effects on recurrent mania and depression in bipolar affective disorder, has a unique suicide risk prevention effect, can effectively relieve anxiety, depression and other emotional abnormalities, can delay central nervous system degenerative changes, and changes the in vivo distribution defects of existing inorganic lithium salt. In addition, the purpose of modifying the physical and chemical properties of a drug can be achieved by adopting a pharmaceutical eutectic or salifying technology without changingthe public valence structure of drug molecules, the clinical dosage of the lithium salt is reduced while the curative effect of central nervous system diseases is enhanced, and the occurrence of peripheral adverse reactions is avoided.

The invention discloses a method for establishing a suicide risk prediction model of a tumor patient. The method comprises the following steps: collecting demographic data; collecting disease-relateddata of a tumor patient; collecting clinical related characteristic data of the tumor patient; collecting the anxiety and depression level, social support conditions, life quality, family functions and smegmatis conditions of the patient in a tumor rehabilitation period; taking whether a tumor patient has a suicide idea or not as a dependent variable to carry out single-factor analysis on relatedfactors possibly influencing the suicide idea, and establishing a column diagram prediction model; and carrying out distinguishing degree and calibration degree evaluation on the column diagram prediction model. The calibration degree of the prediction model can be evaluated through goodness-of-fit test and a correction curve, and the sensitivity and specificity are adopted to determine the prediction truncation value of the column diagram prediction model. According to the invention, the suicide risk grade of a tumor patient can be accurately predicted; the suicide risk of a tumor patient canbe evaluated in time at the terminal, and the clinical decision-making efficiency is improved.